title: Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction.
abstract: BACKGROUND
  An easily accessible and valid surrogate marker for interventional stroke trials is needed.
  
  
  OBJECTIVE
  To investigate the usefulness of various S100B serum measures to predict long-term outcome and infarct volume in patients with acute stroke.
  
  
  METHODS
  Inception cohort study.
  
  
  METHODS
  Tertiary care university hospital.
  
  
  METHODS
  Thirty-nine patients (mean +/- SD age, 69.1 +/- 11.5 years) with acute nonlacunar middle cerebral artery infarction presenting less than 6 hours after symptom onset.
  
  
  METHODS
  Functional outcome 6 months after stroke (modified Rankin scale score) and final infarct volume on day 7 by means of standardized volumetry of brain images. Serum S100B level was determined at hospital admission and 24, 48, 72, 96, 120, and 144 hours after symptom onset.
  
  
  RESULTS
  Single S100B measures obtained 48 and 72 hours after stroke onset demonstrated the highest Spearman rank correlations with modified Rankin scale scores (rho = 0.68 and rho = 0.67, respectively; P<.001) and infarct volume (rho = 0.95 and rho = 0.94, respectively; P<.001). A 48-hour S100B value of 0.37 microg/L or less revealed a sensitivity of 0.87 and a specificity of 0.78 in predicting an independent functional outcome. In a multivariate model, S100B emerged as an outcome predictor that was independent of age, sex, stroke severity, etiology, lesion side, and risk factors.
  
  
  CONCLUSIONS
  Single S100B values obtained 48 and 72 hours after stroke onset provide the highest predictive values with respect to functional outcome and infarct volume in nonlacunar middle cerebral artery infarction. More complex measures of the S100B kinetic (ie, area under the curve or peak value) were not superior. Therefore, these single S100B measures appear to be useful surrogate end points in acute interventional stroke trials.
authors: Department of Neurology, Johann Wolfgang Goethe-University Frankfurt am Main, Frankfurt am Main, Germany. foerch@em.uni-frankfurt.de
authors: Christian
authors: C
authors: Foerch
authors: Oliver C
authors: OC
authors: Singer
authors: Tobias
authors: T
authors: Neumann-Haefelin
authors: Richard
authors: R
authors: du Mesnil de Rochemont
authors: Helmuth
authors: H
authors: Steinmetz
authors: Matthias
authors: M
authors: Sitzer
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D001324:Autoantigens; D015415:Biomarkers / Q000097:blood*; D002544:Cerebral Infarction / Q000473:pathology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020768:Middle Cerebral Artery / Q000473:pathology*; D009414:Nerve Growth Factors / Q000097:blood*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D001324:Autoantigens; D015415:Biomarkers; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human